- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: RPC-1063 | RPC1063 | Zeposia®
ozanimod is an approved drug (EMA & FDA (2020))
Compound class: Synthetic organic
Comment: Ozanimod (RPC1063) is a novel, orally available, specific and potent agonist of the sphingosine 1-phosphate 1 receptor (S1P1R) and SIP5Rs . Ozanimod is compound 86 in patent US20110172202 A1 , which specifies the (S)-enantiomer.
Ozanimod reduces chronic inflammation and alleviates kidney pathology in a mouse model of systemic lupus erythematosus (SLE), which suggests that ozanimod may offer clinical benefit as a SLE therapeutic .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Ozanimod is metabolized to RP-101075, a compound which retains an activity profile indistinguishable from its parent .|
|Selectivity at GPCRs|
|Key to terms and symbols||Click column headers to sort|
|Ligand mentioned in the following text fields|
|Lysophospholipid (S1P) receptors overview|